HomeAI · summaries
Storia in 6 fonti
Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly
Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push ahead.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
swissinfo.ch
Novartis Drug Fails Key Test for New Heart Disease Approach
(Bloomberg) -- A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a final-stage trial, marking a major setback for a…
- ·
biopharmadive.com
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for…
